Medley Therapeutics (formerly YAP Therapeutics) has dosed the first cohort (n=3) with YAP101 in the Phase 1 SALVADOR-HF trial at The Texas Heart Institute at Baylor College of Medicine in the Baylor St. Luke’s Medical Center (Houston). This is the first clinical investigation of a genetic medicine to induce endogenous […]